Understanding how blood stem cells can successfully engraft after transplantation

Mechanisms of hematopoietic stem cell engraftment

['FUNDING_R01'] · UNIVERSITY OF ILLINOIS AT CHICAGO · NIH-11063109

This study is looking at how certain immune cells and a molecule called VCAM1 can help blood stem cells from partially matched donors successfully take root in patients after a transplant, with the goal of making these transplants work better for people with blood cancers and disorders.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorUNIVERSITY OF ILLINOIS AT CHICAGO (nih funded)
Locations1 site (Chicago, UNITED STATES)
Trial IDNIH-11063109 on ClinicalTrials.gov

What this research studies

This research investigates the mechanisms that allow hematopoietic stem cells (HSCs) to successfully engraft in patients after transplantation, particularly focusing on haploidentical transplantation where donors are only partially matched. The study aims to explore the role of innate immune cells and a specific molecule called VCAM1, which may help prevent the rejection of transplanted cells. By manipulating VCAM1 levels, the researchers hope to improve the success rates of these transplants, making them a viable option for more patients with blood cancers and disorders. The approach includes both laboratory experiments and potential clinical applications to enhance patient outcomes.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients requiring hematopoietic stem cell transplantation, particularly those with limited donor options due to HLA mismatches.

Not a fit: Patients who do not require stem cell transplantation or those with fully matched donors may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved transplant outcomes for patients with blood cancers and disorders by reducing the risk of rejection.

How similar studies have performed: Other research has shown promise in manipulating immune responses in transplantation, suggesting that this approach could lead to significant advancements in the field.

Where this research is happening

Chicago, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Conditions: blood cancer

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.